Wnt signaling pathway in retinal vascularization

Kimberly A Drenser
Associated Retinal Consultants, Royal Oak, MI, USA

Abstract: Wnt-signaling, a ubiquitous pathway that directs differentiation, cell polarity, and tissue specificity, has been implicated as an important gene-expression pathway in retinal development. An increasing body of evidence supports the importance of Wnt-signaling, and specifically, norrin-mediated Wnt-signaling in retinal development and retinal maintenance. Gene mutations affecting the Wnt-signaling pathways result in a variety of inherited vitreoretinopathies. Additionally, there is growing evidence that prematurity and associated retinopathy are associated with alterations in the Wnt-signaling pathways. Further investigations may allow for improved diagnoses, management, and therapies in the future.

Keywords: Wnt, norrin, angiogenesis, development, ROP, prematurity

Background

Wnt-signaling is a ubiquitous pathway that modulates cellular and tissue differentiation. The Wnt gene family consists of 19 structurally related genes, which encode cysteine-rich secreted glycoproteins that act as extracellular signaling factors. Wnt proteins can signal in a variety of ways, depending on the cell type and the receptors and/or co-receptors expressed. Extracellular Wnt ligands interact with their transmembrane Fzd receptors of which there are currently ten identified isoforms in humans, and thereby, activate three diverse signaling pathways. Binding of the Wnt ligand to its Fzd receptor simultaneously with a co-receptor, the low-density LRP5/6, initiates the canonical pathway. This leads to modulation in the transcription of over 50 genes in mammals.

The canonical Wnt/β-Catenin pathway is the most thoroughly studied. In the retina, activation is initiated by ligand binding to both the Fzd4 receptor and its co-receptor, LRP5. Multiple Wnt ligands (3a, 5a, 7a, 10a, norrin) are able to bind the Fzd4 receptor. Binding of the receptor complex activates the Dsh protein. This ultimately results in dephosphorylation of β-Catenin and its subsequent translocation to the nucleus. Nuclear β-Catenin participates as a transcriptional activator of the TCF/LEF-1 family of DNA binding proteins. Target genes include c-myc, CCND1, and VEGF, which presumably regulates cell proliferation in specific tissues.

The planar cell polarity pathway also involves activation of Dsh protein following Fzd4 binding. Unlike the canonical pathway, a co-receptor (LRP5) is not needed for signal activation. One of two small GTPases (Rho or Rac) is thereby activated, which in turn activate an alternative signal transduction pathway. The planar cell polarity
pathway mediates cytoskeletal organization and cell migration during development and tissue maturation.

The Wnt-Ca\(^{2+}\) pathway (noncanonical signaling) is the least characterized cascade. In the Wnt-Ca\(^{2+}\) pathway, Fzd receptor activation stimulates an intracellular Ca\(^{2+}\) release, activating CamKII and PKC. This pathway directs cell adhesion and cell movement and is necessary for normal development. Wnt5a is a potent activator of this pathway.\(^3\)

In regards to eye development, a particular Wnt-pathway, norrin-Fzd4, has been identified as playing an essential role in normal retinal angiogenesis. Signaling through the norrin-Fzd4 (canonical and noncanonical) pathways is necessary for the development and maintenance of retinal vasculature.\(^4,7\) Conversely, increased expression of other Wnt ligands (Wnts 3a, 5a, 7a, and 10a) has been associated with pathologic angiogenesis (neovascularization) in animal models of retinopathy and proliferative diabetic retinopathy.\(^8\) Without proper activation, dysregulated angiogenesis leads to pathological vascular changes, such as breakdown of tight junctions, capillary drop-out, endothelial budding, and neovascularization, and in extreme cases development of primitive vascular trees (vasculogenesis only). Patients with gene mutations affecting Wnt signaling result in several pediatric vitreoretinopathies, such as Norrie disease, familial exudative vitreoretinopathy (FEVR), and pseudoglioma and osteoporosis syndrome.\(^9-16\) Additionally, retinopathy of prematurity (ROP) has been associated with gene mutations affecting Wnt signaling.\(^14, 17-20\) Although Coats’ disease and persistent fetal vasculature (PFV) are generally unilateral and sporadic, Wnt-pathway mutations have been reported.\(^21-23\)

**Retinal vasculogenesis and angiogenesis**

Vasculogenesis is the de novo synthesis of blood vessels. In the human retina the early development of vasculature begins posteriorly, at the optic nerve head. There is clear evidence that vascularization beyond the early stages of vasculogenesis does not occur without norrin-Fzd4 signaling.\(^18\) Infants with Norrie disease often express mutations in norrin that either eliminates norrin protein translation or affects the tertiary structure, thereby disallowing norrin-Fzd4 binding. Point mutations of the conserved cysteine residues result in improper protein folding. Patients with these mutations have primitive vasculogenesis only and minimal regression of the primary hyaloid structures (Figure 1).

Angiogenesis is the growth of new vessels from existing vessels by way of endothelial budding. When properly controlled, normal retinal development with branching vessels and capillary networks occur. When this is dysregulated, incomplete vascularization and/or pathologic angiogenesis develop (Figure 2).\(^1,4,7\) This can often represent a spectrum of disease severity. In the premature infant, the earliest sign of abnormal angiogenesis is seen as a cessation of retinal vasculature growth. This is primarily an effect of decreased circulating VEGF but is exacerbated by other proangiogenic factors being dysregulated as well. It has been shown in animal models that Wnt pathway activation by norrin is able to overcome this delay in vascular development.\(^24,25\) Intravitreal injection of norrin following oxygen exposure greatly accelerates the retinal recovery and vascular maturation in the oxygen-induced retinopathy mouse model.\(^24\) Endogenous expression of norrin in the eye by way of virally transfected lens epithelial cells is protective from oxygen-induced retinopathy and no abnormal retinal development is seen.\(^25\)
Norrin may protect the developing eye from abnormal angiogenesis and retinopathy by modulating Wnt signaling as well. A comparison of room air mice and oxygen-induced retinopathy (OIR) mice showed significant changes in the expression of Wnt ligands that bind and activate the Fzd4 receptor. Messenger RNA is significantly increased for Wnts 3a, 7a, and 10a but not for norrin during the development of retinopathy.26 This indicates that norrin provides a protective effect, in part, by modulating the activity of other Wnts when they are pathologically upregulated.

Nonfenestrated vessels

Retinal vessels are highly specialized nonfenestrated vessels, as seen in the central nervous tissue. This requires vessels to have tight junctions, formed by claudins and occludens, which prevents passive movement of fluids and proteins through the vessel walls.27,28

Claudins are integral transmembrane proteins necessary for tight junction formation.28 CLD5 is expressed by retinal endothelial cells. At the cellular level, Wnt signaling modulates tight-junction maintenance in the retinal vessels by upregulating expression of CLD5.29–31 Disrupted norrin-Fzd4 binding leads to decreased expression of CLD5 and breakdown of the blood–retinal barrier.4,26 Although there is evidence that norrin activates all three of the intracellular Wnt pathways,32–35 loss of the co-receptor LRP5 results in decreased expression of CLD5, indicating that tight junction formation and maintenance is primarily driven by the canonical pathway.26

Neurogenesis

Norrin is a small secreted protein with a cysteine-knot motif.14–16 The cysteine-knot motif is highly conserved in many growth factors, including TGF-β, human chorionic gonadotropin, NGF, and PDGF. The structural similarity of norrin to other growth factors suggests that it may have a function in addition to traditional Wnt-signaling, despite the fact that it is best characterized as a Wnt-receptor ligand. This theory is supported by its lack of structural similarity to other Wnt proteins.17

Norrin’s role in neurogenesis and neuroprotection is just being elucidated and appears to be multifactorial. Recent investigations have uncovered that norrin acts as a ligand for LGR4, a receptor for Wnt activation that regulates neurogenesis.36 Recent mapping of LGR4 expression in the retina shows that it is expressed by Mueller cells, photoreceptor inner segments, retinal ganglion cells, and bipolar cells (Figure 3). This suggests that norrin has multiple roles in the formation of the neurovascular unit in the retina. Norrin neuroprotection has been reported in models of retinal toxicity. Seitz et al reported increased survival of retinal ganglion cell (RGC) axons and decreased apoptosis in N-methyl-D-aspartate-injected mice following simultaneous injection with norrin.37 The authors concluded that norrin’s protective effect on RGCs was caused by an increase of Muller cell neurotrophic growth factor expression. Norrin neuroprotection has been demonstrated in the photoreceptors, as well. Braunger and Tamm reported that norrin provided protection against light damage to photoreceptors in mice overexpressing norrin in their RPE cells.38 The authors proposed that norrin provides protection to the photoreceptors by increasing the expression of neurotrophic growth factors, specifically BDNF. It is plausible that norrin provides protection to RGCs in OIR eyes by increasing the expression of Muller cell derived neurotrophic factors and, thereby, preventing excitotoxicity and subsequent loss of RGCs.

Clinical manifestations

To various degrees, eyes with Wnt-associated vitreoretinopathies exhibit incomplete peripheral vascularization, incomplete regression of the primary hyaloid system, capillary drop-out, endothelial budding, and breakdown of the blood–retina barrier, often leading to exudative and tractional retinal detachments.15–18 Norrie disease is an X-linked disorder and has the most severe phenotype resulting in blindness, often present at birth. It is often caused by mutations in the conserved cysteine residues of the NDP gene, which comprise the necessary tertiary structure involved in ligand–receptor binding.19 In PFV, the premature vasculature of the eye does not regress appropriately, resulting in the formation of a fibrous stalk that extends from the optic disk to the posterior lens capsule. Since the fibrous stalks are common in both PFV and Norrie Disease, the two disorders are often indistinguishable if bilateral disease is present. FEVR occurs
in X-linked (NDP), autosomal recessive (LRP5), and autosomal dominant inheritance patterns (Fzd4, TSpan12, ZNF408). Most reported cases of AdFEVR have been associated with heterozygous mutations in the Fzd4 gene.14,16 A unifying characteristic in these diseases is an aberration of retinal vascular development demonstrating varying degrees of peripheral avascular retina, abnormal vascularization with retinal neovascularization, and subretinal exudation.

**Wnt signaling and ROP**

ROP and FEVR have overlapping phenotypes and an ambiguous birth history may confuse the diagnosis. Generally, ROP is distinguished from FEVR by premature birth and lack of a family history of eye disease. A combination of incomplete peripheral retinal vessel development and exposure to a relatively high oxygen environment (compared to in utero) is believed to set the stage for development of ROP. However, gestational age (GA), birth weight, and systemic health alone do not predict the progression to retinopathy, thus requiring that all at-risk infants have routine screening exams every 1–2 weeks. The overlap in retinal characteristics has supported the hypothesis that a predisposition for ROP is created by genetic alterations. In fact, a twin study demonstrated that there is a likely genetic predisposition for ROP development in 80% of premature infants with retinopathy.38 Mutations in both the NDP and Fzd4 genes have been reported in ROP cases and make Wnt-pathway mutations a likely candidate as a risk factor for developing ROP.14,17–20,39

Several studies have reported Fzd4, NDP, and LRP5 gene mutations in ROP patients and these appear to be particularly associated with more severe ROP.13–20,30,37 The first report discovered mutations located in the 5’ untranslated region of the NDP gene.30 A subsequent study found 13% (7/53) of infants with advanced ROP had either Fzd4 (n=3) or LRP5 (n=4) mutations.17 Similarly, Ells et al found three Fzd4 mutations (Arg466Trp, Ala370Gly, Lys203Asn) in a group of 71 severe ROP patients and no Fzd4 mutations in 33 patients with mild or no ROP.20 Both studies concluded that Fzd4 mutations may have a role in the development or exacerbation of ROP. Ells et al also found the compound variation (P33S;P168S) or either mutation alone in 10% of their severe ROP patients and in only 3% of patients with mild to no ROP. However, since they also found (P33S;P168) in 7% of subjects in a group of random Caucasian samples, they could not make a conclusion regarding the causality of the variation. A recent publication confirmed this finding noting a high association with the Fzd4 compound variation (P33S;P168S) and ROP. In this study, a large patient database (n=519) was analyzed for mutations affecting the Wnt-signaling pathway.41 Infants diagnosed with ROP had the highest frequency of the (P33S;P168S) variation (7.5%) compared to FEVR, possible FEVR, Norrie disease or bilateral PFV. In contrast, the rate in healthy newborns (3.1%) was not significantly different from that predicted based on the subjects in the 1,000 Genomes project, with a prevalence of the (P33S;P168S) variation in 20 out of 1,092 random subjects (1.8%).

**Role of Wnt signaling in fetal development**

The link between premature birth and ROP may lie with altered Wnt signaling. Studies have shown that norrin-Fzd4 signaling affects angiogenesis in the female reproductive system. Markers for angiogenesis and vascular formation are reduced in the corpora lutea of Fzd4 null mice and these mice are infertile.42 Also, Fzd4 mRNA localizes to vessels and stroma surrounding the mouse embryo.43 Similarly, norrin has been localized to the uterine blood vessels and decidual cells of rats,44 and NDP knockout mice have defects in vascular development and decidualization in pregnancy that leads to embryonic loss.45 In humans, the expression of NDP has been established in the placenta, and Fzd4 expression has been localized to placental villous mesenchymal cells.46

Infants expressing the (P33S;P168S) Fzd4 variant have significantly reduced weight for GA.41 The lower than normal birth weights for GA present in the ROP patients with the (P33S;P168S) variant compared to the other premature infants supports the theory that the Fzd4 receptor is involved in placental formation and/or fetal growth. In fact, five of seven ROP patients with the variation were in the group that had the highest birth weight deficits and were defined as small for gestational age. Presumably, the presence and/or absence of the sequence variation in the mothers would also be a complicating factor in fertility and/or placental development as would additional mutations in NDP; Fzd4 pathway genes.41

**Summary**

The Wnt signaling pathway plays a critical role in retinal development, in regard to both angiogenesis and neurogenesis. It is also vital for normal fetal growth and may be a predictor for placental insufficiency and preterm birth. Specifically, Wnt activation through proper norrin:Fzd4 binding is specific to retinal development. Alterations affecting this pathway often result in Wnt-associated vitreoretinopathies and may be a risk factor for developing ROP. Therefore, it may be beneficial to screen premature infants for the presence of Wnt signaling mutations so that these patients may
be monitored more carefully. Additionally, patients with anomalous vasculature and displaying any of the characteristics commonly seen with Wnt-pathway mutations should be offered genetic testing.

Disclosure
The author has no conflicts of interest to disclose.

References


